

REVISED TABLE 10: Summary of Boys and Men 9 Through 26 Years of Age Who Reported an Incident Condition Potentially Indicative of a Systemic Autoimmune Disorder After Enrollment in Clinical Trials of GARDASIL, Regardless of Causality

HPV INSERT REVISED TABLE 10 (see Plotkin Deposition)				
Conditions	AAHS Control* & Saline Placebo (N = 2,303) n (%)	GARDASIL (N = 3,092) n (%)	Only AAHS Control* (N = 2,029) n (%)	Only Saline Placebo (N= 274) n (%)
Alopecia Areata	0 (0.0)	1 (0.0)	0 (0.0)	0 (0.0)
Ankylosing Spondylitis	2 (0.1)	1 (0.0)	2 (0.1)	0 (0.0)
Arthralgia/Arthritis/Reactive Arthritis	17 (0.7)	30 (1.0)	17 (0.7)	0 (0.0)
Autoimmune Thrombocytopenia	0 (0.0)	1 (0.0)	0 (0.0)	0 (0.0)
Diabetes Mellitus Type 1	2 (0.1)	3 (0.1)	2 (0.1)	0 (0.0)
Hyperthyroidism	1 (0.0)	0 (0.0)	1 (0.0)	0 (0.0)
Hypothyroidism**	0 (0.0)	3 (0.1)	0 (0.0)	0 (0.0)
Inflammatory Bowel Disease***	2 (0.1)	0 (0.0)	2 (0.1)	0 (0.0)
Myocarditis	1 (0.0)	1 (0.0)	1 (0.0)	0 (0.0)
Proteinuria	0 (0.0)	1 (0.0)	0 (0.0)	0 (0.0)
Psoriasis	2 (0.1)	0 (0.0)	2 (0.1)	0 (0.0)
Vitiligo	5 (0.2)	2 (0.1)	5 (0.2)	0 (0.0)
All Conditions	32 (1.4)	43 (1.4)	32 (1.4)	0 (0.0)

See Plotkin Deposition. Video at tinyurl.com/HPV-Placebo-Study; Transcript pages 197-202, at tinyurl.com/Plotkin-Deposition-Transcript

Calculating AAHS Only Group: 2,303 - 274 = 2,029. Saline Placebo Group representation of total combined group: 274/2,029 = 013.50%

The number 274 referenced as the Saline Placebo group comes from Table 2, Saline Placebo (N = 274)

Calculating AAHS Only Group percentage of reported conditions: n/2,029. Only one decimal point used, as in combined group.

*AAHS Control = Amorphous Aluminum Hydroxyphosphate Sulfate

**Hypothyroidism includes the following terms: Hypothyroidism and Autoimmune thyroiditis

*** Inflammatory bowel disease includes the following terms: Colitis ulcerative and Crohn's disease

N = Number of individuals enrolled

n = Number of individuals with specific new Medical Conditions, percentage in total group

© PRBWorks